Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.

Abstract: The field of the invention is site-specific drug delivery capsules (SSDC's). The disclosure relates to a closure member (14) for a substance reservoir (12) of an SSDC (10). The SSDC (10) includes a retainer that provides a non-linear force resisting opening of the closure member (14). The non-linear force ensures that the closure member (14) unseals the reservoir (12) only when an opening force exceeds a maximal value of the resisting force, thereby preventing premature or accidental emptying of the reservoir (12). The preferred means of providing the resistive force is a rolling, elastomeric o-ring (64) that additionally seals the closure member (14) into an aperture (13).

Abstract: The field of the invention is site-specific drug delivery capsules (SSDC's). The disclosure relates to a closure member (14) for a substance reservoir (12) of an SSDC (10). The SSDC (10) includes a retainer that provides a non-linear force resisting opening of the closure member (14). The non-linear force ensures that the closure member (14) unseals the reservoir (12) only when an opening force exceeds a maximal value of the resisting force, thereby preventing premature or accidental emptying of the reservoir (12). The preferred means of providing the resistive force is a rolling, elastomeric o-ring (64) that additionally seals the closure member (14) into an aperture (13).